Amobarbital Sodium

CHEMBL2105941 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
248.2 g/mol
LogP
Phase
4

The sodium salt form of amobarbital, a barbiturate that acts on GABA receptors in the brain to produce sedation and sleep. Like other barbiturates, it carries risks of tolerance, dependence, and overdose.

น้ำหนักโมเลกุล

248.2500 g/mol

TPSA

81.60 Ų

กลไกการออกฤทธิ์

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC1(CCC(C)C)C(=O)N=C([O-])NC1=O.[Na+]

InChI

InChI=1S/C11H18N2O3.Na/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1

Molecular Formula

C11H17N2NaO3

HBD / HBA

1 / 3

พันธะที่หมุนได้

4

อะตอมหนัก

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The sodium salt form of amobarbital, a barbiturate that acts on GABA receptors in the brain to produce sedation and sleep. Like other barbiturates, it carries risks of tolerance, dependence, and overdose.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Amobarbital Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105941. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23689390. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.